Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Feb 28;9(3):648. doi: 10.3390/jcm9030648

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2020 by the authors.

Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).

PMC Copyright notice

Survival according to first line and second line treatment for most popular regimens. Kaplan-Meier curves of patients who were treated with one of the most popular second line treatment regimes, calculated from the initiation of the first (A) and second (B) treatment line according to the year when the first systemic treatment was administered. The most popular treatment lines were gemcitabine/nab-paclitaxel, gemcitabine/(capecitabine)/erlotinib, as well as fluoropyrimidines/oxaliplatin for the cohort 2011–2013 and fluoropyrimidines/nanoliposomal irinotecan, as well as fluoropyrimidines/oxaliplatin for the cohort 2014–2017.